Niemann-Pick Disease Type C: Integrating FDA-Approved Therapies and Best Practices in Patient Management

What you'll learn

Course overview

Advancements in the treatment of Niemann-Pick Disease Type C (NPC) have transformed the therapeutic landscape, with the FDA approval of novel disease-modifying therapies offering new hope for patients. Healthcare professionals must stay informed about these developments to provide evidence-based care that optimizes patient outcomes. Understanding the mechanisms of action, indications, contraindications, and monitoring requirements of newly approved treatments such as arimoclomol and miglustat is essential for integrating these therapies into clinical practice. Additionally, the expanding pipeline of investigational treatments, including gene therapy and substrate reduction strategies, underscores the importance of staying current with emerging research. This course equips healthcare professionals with the knowledge needed to navigate the complexities of NPC management, ensuring early diagnosis, informed treatment decisions, and a multidisciplinary approach to patient care.